Evidence map›Paper›PMID 37662924›Full record

ArticleFrontiers in immunology2023

Systematic Mendelian randomization study of the effect of gut microbiome and plasma metabolome on severe COVID-19.

Han Yan, Si Zhao, Han-Xue Huang, Pan Xie, Xin-He Cai, Yun-Dan Qu, Wei Zhang, Jian-Quan Luo, Longbo Zhang, Xi Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Han YanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Si ZhaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Han-Xue HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Pan XieDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin-He CaiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yun-Dan QuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jian-Quan LuoDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Longbo ZhangDepartments of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, Hunan, China.
Xi LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNPharmacoGenetics (China) · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 could develop severe respiratory symptoms in certain infected patients, especially in the patients with immune disorders. Gut microbiome and plasma metabolome act important immunological modulators in the human body and could contribute to the immune responses impacting the progression of COVID-19. However, the causal relationship between specific intestinal bacteria, metabolites and severe COVID-19 remains not clear. Methods: Based on two-sample Mendelian randomization (MR) framework, the causal effects of 131 intestinal taxa and 452 plasma metabolites on severe COVID-19 were evaluated. Single nucleotide polymorphisms (SNPs) strongly associated with the abundance of intestinal taxa and the concentration of plasma metabolites had been utilized as the instrument variables to infer whether they were causal factors of severe COVID-19. In addition, mediation analysis was conducted to find the potential association between the taxon and metabolite, and further colocalization analysis had been performed to validate the causal relationships. Results: MR analysis identified 13 taxa and 53 metabolites, which were significantly associated with severe COVID-19 as causal factors. Mediation analysis revealed 11 mediated relationships. Myo-inositol, 2-stearoylglycerophosphocholine, and alpha-glutamyltyrosine, potentially contributed to the association of Conclusions: Our study highlights the potential causal relationships between gut microbiome, plasma metabolome and severe COVID-19, which potentially serve as clinical biomarkers for risk stratification and prognostication and benefit the mechanism mechanistic investigation of severe COVID-19.

Indexed as

COVID-19Gastrointestinal MicrobiomeHumansMediation AnalysisMendelian Randomization AnalysisMetabolomeCOVID-19gut microbiomemediation analysisMendelian randomization analysisplasma metabolites

Identifiers

PMID37662924
PMCPMC10468967
OpenAlexW4385954683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.